- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT07531966
Сосудистые осложнения после трансплантации почки (DAN-PTRAIII)
Сосудистые осложнения после трансплантации почки: проспективное национальное многоцентровое исследование - исследование DAN-PTRAIII
- To determine the incidence of arterial inflow problems and venous outflow problems as causes of impaired renal function and/or treatment-resistant hypertension after kidney transplantation, when all kidney-transplant recipients in Denmark are evaluated according to uniform, well-defined clinical criteria.
- To investigate the efficacy and safety of catheter-based balloon treatment (percutaneous transluminal angioplasty, PTA) for these vascular complications, of which transplant renal artery stenosis is by far the most common.
- To assess whether novel imaging and functional diagnostic methods can predict treatment response.
Обзор исследования
Статус
Условия
Подробное описание
Kidney transplantation is performed 250-300 times annually in Denmark and substantially improves survival, quality of life, and reduces the burden of comorbidities in patients with end-stage kidney disease. Despite these benefits, vascular complications, particularly transplant renal artery stenosis (TRAS), remain a major cause of morbidity. Reported incidence of TRAS varies widely (1-23%), reflecting retrospective study designs and inconsistent diagnostic criteria. TRAS are classified into three main types: anastomotic (TRAS-A), post-anastomotic (TRAS-P), and long-segment bend/kink (TRAS-B), with most cases diagnosed within the first two years post-transplant. Severe stenoses can critically impair graft perfusion, leading to reduced renal function and treatment-resistant hypertension.
Percutaneous transluminal angioplasty (PTA) for TRAS is a well-established procedure performed according to the same principles as coronary balloon angioplasty; however, the role of stent placement remains uncertain. PTA without stenting is associated with higher restenosis rates compared to PTA with stenting, yet evidence regarding graft function, survival, and blood-pressure control remains conflicting.
Adverse events related to PTA occur in approximately 10% of patients and are generally mild. Serious adverse events are observed in fewer than 5% of patients and include procedure-related internal bleeding and vascular access-site complications. Severe internal bleeding may require blood transfusion and endovascular vessel occlusion and can, in rare cases, result in loss of the transplanted kidney. Access-site vascular complications may present as bleeding, thrombosis, or pseudoaneurysm.
Against this background, the nationwide prospective multicentre DAN-PTRAIII study aims to establish the true incidence of arterial inflow and venous outflow problems in Danish kidney-transplant recipients, evaluate the efficacy and safety of balloon angioplasty, and explore novel imaging and functional diagnostic methods for predicting treatment response.
Тип исследования
Регистрация (Оцененный)
Контакты и местонахождение
Контакты исследования
- Имя: Mark Reinhard, MD, PhD
- Номер телефона: +45 40460321
- Электронная почта: markrein@rm.dk
Учебное резервное копирование контактов
- Имя: Henrik Birn, MD, DMSc
- Электронная почта: hb@clin.au.dk
Места учебы
-
-
-
Aarhus, Дания, 8200
- Рекрутинг
- Aarhus University Hospital
-
Контакт:
- Mark Reinhard, MD, PhD
- Электронная почта: markrein@rm.dk
-
Copenhagen, Дания, 2100
- Рекрутинг
- Rigshospitalet
-
Контакт:
- Søren S Sørensen, MD, DMSc
- Электронная почта: Soeren.Schwartz.Soerensen@regionh.dk
-
Odense, Дания, 5000
- Рекрутинг
- Odense University Hospital
-
Контакт:
- Claus Bistrup, MD, PhD
- Электронная почта: Claus.Bistrup@rsyd.dk
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Метод выборки
Исследуемая популяция
National prospective multicenter study with a primary endpoint at 3 months and annual follow-up for up to 10 years post-intervention, evaluating renal function, blood pressure, and clinical events.
Patients with vascular complications, predominantly transplant renal artery stenosis (TRAS) following kidney transplantation, who meet at least one of the clinical inclusion criteria, may be enrolled in the study.
Описание
Inclusion Criteria:
1. At least one of the following clinical criteria (1 or 2) must be fulfilled:
-
Graft dysfunction, defined by at least one of the following:
- Acute reduction in estimated glomerular filtration rate (eGFR) >15% on two consecutive measurements at least 2 weeks apart, with other causes excluded (rejection, obstruction, infection).
- eGFR <50% of the expected value 30 days after kidney transplantation of unknown cause.
- Decline in eGFR >30% after initiation of an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker.
-
Persistent resistant hypertension for more than 6 weeks after kidney transplantation, defined as:
- 24-hour ambulatory systolic blood pressure >130 mmHg despite treatment with at least three classes of antihypertensive medication at maximally tolerated doses (including diuretics, if tolerated).
Together with at least one of the following radiological criteria:
-
CT or MR angiography demonstrating a lumen reduction ≥50%.
-
Doppler ultrasound showing:
- Peak systolic velocity in the renal artery ≥200 cm/s and a renal-renal ratio (velocity at stenosis / velocity in distal artery) >4.
- Acceleration time >70 ms in intrarenal arteries.
2. In cases of strong clinical suspicion of a vascular complication where CT or MR angiography cannot reliably exclude graft artery or vein stenosis, patients may be referred for confirmatory invasive investigations.
Before PTA, catheter-based angiography and translesional pressure measurements are performed to confirm whether the patient meets the radiological eligibility criterion for PTA:
-
Stenosis ≥70%.
-
Stenosis 50-69% if at least one of the following criteria is met:
- Mean translesional pressure gradient ≥10 mmHg.
- Systolic pressure gradient ≥20 mmHg.
- Renal Pd/Pa ≤0.8.
- If pressure measurements cannot be obtained, treatment is based on the operator's clinical judgement.
Exclusion Criteria:
- Inability to provide informed consent.
- Concurrent biopsy demonstrating rejection requiring treatment.
- Pregnancy.
- Previous PTA of the same vessel.
- Patients unable to tolerate any form of antithrombotic therapy and therefore not eligible for stent placement.
Учебный план
Как устроено исследование?
Детали дизайна
- Наблюдательные модели: COHORT
- Временные перспективы: PROSPECTIVE
Когорты и вмешательства
Группа / когорта |
Вмешательство/лечение |
|---|---|
|
Kidney Transplant Recipients
Patients who meet well-defined clinical and radiological criteria for significant vascular complications after kidney transplantation, with transplant renal artery stenosis being by far the most common. |
Catheter-based angiography performed in accordance with the study protocol. Measurement of translesional pressure gradients performed in accordance with the study protocol. Intravascular ultrasound (IVUS) performed in accordance with the study protocol. Percutaneous transluminal angioplasty (PTA) is performed in accordance with the study protocol. As a general principle, bare-metal stents (BMS) are used. Drug-eluting stents (DES) may be considered when the arterial lumen diameter is < 4-5 mm. In stenoses where stent placement carries a risk of side-branch occlusion, PTA is performed without stent implantation and most often with a drug-coated balloon (DCB). |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Change in measured glomerular filtration rate (mGFR).
Временное ограничение: Baseline and 3 months post-PTA.
|
Change in measured glomerular filtration rate (mGFR) at 3 months post-PTA compared with baseline. |
Baseline and 3 months post-PTA.
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Change in estimated glomerular filtration rate (eGFR).
Временное ограничение: Baseline, Day 1, Day 7, Day 21, 6 weeks, 3 months, 12 months, and annually thereafter for up to 10 years post-PTA.
|
Change in estimated glomerular filtration rate (eGFR) measured on day 1, day 7, day 21, at 6 weeks, at 3 and 12 months, and annually thereafter for up to 10 years post-PTA, compared with baseline. |
Baseline, Day 1, Day 7, Day 21, 6 weeks, 3 months, 12 months, and annually thereafter for up to 10 years post-PTA.
|
|
Change in home systolic blood pressure.
Временное ограничение: Baseline, Day 7, Day 21, 6 weeks, 3 months, 12 months, and annually thereafter for up to 10 years post-PTA.
|
Change in home systolic blood pressure measured on day 7, day 21, at 6 weeks, at 3 and 12 months, and annually thereafter for up to 10 years post-PTA, compared with baseline. |
Baseline, Day 7, Day 21, 6 weeks, 3 months, 12 months, and annually thereafter for up to 10 years post-PTA.
|
|
Change in attended automated office systolic blood pressure.
Временное ограничение: Baseline, 3 months, 12 months, and 24 months post-PTA.
|
Change in attended automated office systolic blood pressure measured at 3, 12, and 24 months post-PTA, compared with baseline. |
Baseline, 3 months, 12 months, and 24 months post-PTA.
|
|
Change in unattended automated office systolic blood pressure.
Временное ограничение: Baseline, 3 months, 12 months, and 24 months post-PTA.
|
Change in unattended automated office systolic blood pressure measured at 3, 12, and 24 months post-PTA, compared with baseline. |
Baseline, 3 months, 12 months, and 24 months post-PTA.
|
|
Change in 24-hour ambulatory systolic blood pressure.
Временное ограничение: Baseline, 3 months, 12 months, and 24 months post-PTA.
|
Change in 24-hour ambulatory systolic blood pressure measured at 3, 12, and 24 months post-PTA, compared with baseline. |
Baseline, 3 months, 12 months, and 24 months post-PTA.
|
|
Change in defined daily dose (DDD) of antihypertensive medications.
Временное ограничение: Baseline, 3 months, 12 months, and 24 months post-PTA.
|
Change in defined daily dose (DDD) of antihypertensive medications at 3, 12, and 24 months post-PTA compared with baseline. |
Baseline, 3 months, 12 months, and 24 months post-PTA.
|
|
Change in the number of antihypertensive medications.
Временное ограничение: Baseline, 3 months, 12 months, and 24 months post-PTA.
|
Change in the number of antihypertensive medications at 3, 12, and 24 months post-PTA compared with baseline. |
Baseline, 3 months, 12 months, and 24 months post-PTA.
|
|
Change in 24-hour ambulatory systolic blood pressure adjusted for changes in antihypertensive medication.
Временное ограничение: Baseline, 3 months, 12 months, and 24 months post-PTA.
|
Change in 24-hour ambulatory systolic blood pressure measured at 3, 12, and 24 months post-PTA, compared with baseline, adjusted for changes in antihypertensive medication (5 mmHg per DDD). |
Baseline, 3 months, 12 months, and 24 months post-PTA.
|
|
Health status on 12-item Short Form Health Survey (SF-12).
Временное ограничение: Baseline and 3 months post-PTA.
|
Change in 12-item Short Form Health Survey (SF-12) scores at 3 months post-PTA, compared with baseline. Scores range from 0 to 100, with higher scores indicating better physical and mental health functioning. |
Baseline and 3 months post-PTA.
|
|
Number of clinical events after PTA.
Временное ограничение: 10 years post-PTA.
|
Cardiovascular and renal events are defined according to the criteria used in the DAPA-CKD study, with the modification that end-stage kidney disease is defined exclusively as either kidney transplantation or chronic dialysis. After PTA treatment, the following clinical events will be recorded for 10 years:
|
10 years post-PTA.
|
|
Number of adverse events (AEs) occurring within 30 days after the procedure
Временное ограничение: 30 days post-PTA.
|
All adverse events (AEs) occurring within 30 days after the procedure will be recorded and classified according to seriousness, relationship to the procedure, and whether the event occurs within ≤24 hours (periprocedural) or >24 hours through day 30 (post-interventional):
|
30 days post-PTA.
|
|
Doppler ultrasound.
Временное ограничение: Baseline and 3 months post-PTA.
|
Diagnostic utility and predictive value for treatment response to PTA. |
Baseline and 3 months post-PTA.
|
|
Invasive pressure measurements across stenoses.
Временное ограничение: Baseline and 3 months post-PTA.
|
Diagnostic utility and predictive value for treatment response to PTA. |
Baseline and 3 months post-PTA.
|
|
Intravascular ultrasound.
Временное ограничение: Baseline and 3 months post-PTA.
|
Diagnostic utility and predictive value for treatment response to PTA. |
Baseline and 3 months post-PTA.
|
|
Non-invasive fractional flow reserve computed tomography (FFR-CT) / computational fluid dynamics (CFD) simulation.
Временное ограничение: Baseline and 3 months post-PTA.
|
Diagnostic utility and predictive value for treatment response to PTA. |
Baseline and 3 months post-PTA.
|
|
Functional magnetic resonance imaging.
Временное ограничение: Baseline and 3 months post-PTA.
|
Diagnostic utility and predictive value for treatment response to PTA. |
Baseline and 3 months post-PTA.
|
Соавторы и исследователи
Спонсор
Соавторы
Следователи
- Главный следователь: Mark Reinhard, MD, PhD, Aarhus University Hospital
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
- Урогенитальные заболевания
- Сосудистые заболевания
- Сердечно-сосудистые заболевания
- Мужские мочеполовые заболевания
- Заболевания почек
- Урологические заболевания
- Женские урогенитальные заболевания
- Женские мочеполовые заболевания и осложнения беременности
- Сердечные заболевания
- Гипертония
- Гипертония, почечная
- Сердечная недостаточность
- Гипертензия, реноваскулярная
- Следственные методы
- Терапия
- Диагностические методы и процедуры
- Диагноз
- Хирургические процедуры, оперативные
- Катетеризация
- Эндоваскулярные процедуры
- Сосудистые хирургические процедуры
- Сердечно -сосудистые хирургические процедуры
- Минимально инвазивные хирургические процедуры
- Диагностическая визуализация
- Ультрасонография
- Ангиопластика
- Интервенционная ультрасонография
Другие идентификационные номера исследования
- DAN-PTRAIII
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .